Dienolone

From Wikipedia, the free encyclopedia
Dienolone
Clinical data
Other namesRU-3118; Nordienolone
ATC code
  • None
Identifiers
  • (8S,13S,14S,17S)-17-hydroxy-13-methyl-2,6,7,8,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-one
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.125.823 Edit this at Wikidata
Chemical and physical data
FormulaC18H24O2
Molar mass272.388 g·mol−1
3D model (JSmol)
  • CC12CCC3=C4CCC(=O)C=C4CCC3C1CCC2O
  • InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10,15-17,20H,2-9H2,1H3/t15-,16+,17+,18+/m1/s1
  • Key:PUQSDJZESAQGQS-OWSLCNJRSA-N

Dienolone (developmental code name RU-3118; online product names Trenazone,[1] Dienazone), or nordienolone, also known as 19-nor-δ9(10)-testosterone, δ9(10)-nandrolone, or estra-4,9(10)-dien-17β-ol-3-one, is a synthetic anabolic-androgenic steroid (AAS) of the 19-nortestosterone group that was never marketed.[2] It has been found to possess slightly lower affinity for the androgen receptor (AR) and progesterone receptor (PR) relative to nandrolone in rat and rabbit tissue bioassays, whereas trenbolone was found to possess the same affinity for the AR as dienolone but several-fold increased affinity for the PR.[3] Dienedione (the 17-keto analogue of dienolone, also known as 19-nor-4,9-androstadienedione) is thought to be a prohormone of dienolone,[4] while methyldienolone and ethyldienolone are orally active 17α-alkylated AAS derivatives of dienolone.[5][6] In contrast, dienogest, the 17α-cyanomethyl derivative of dienolone, is a potent progestogen and antiandrogen.[7]

See also[edit]

References[edit]

  1. ^ Waller CC, McLeod MD (December 2014). "A simple method for the small scale synthesis and solid-phase extraction purification of steroid sulfates". Steroids. 92: 74–80. doi:10.1016/j.steroids.2014.09.006. hdl:1885/15429. PMID 25286236. S2CID 11504510.
  2. ^ https://isomerdesign.com/Cdsa/HC/StatusDecisions/A-2013-00235%20-%20PDFs/C-Dienolone-2011-08-12.pdf[bare URL PDF]
  3. ^ Ojasoo T, Delettré J, Mornon JP, Turpin-VanDycke C, Raynaud JP (1987). "Towards the mapping of the progesterone and androgen receptors". Journal of Steroid Biochemistry. 27 (1–3): 255–269. doi:10.1016/0022-4731(87)90317-7. PMID 3695484.
  4. ^ "2009 - Final Rule: Classification of Three Steroids as Schedule III Anabolic Steroids Under the Controlled Substances Act".
  5. ^ Thevis M, Schanzer W (18 December 2009). "Synthetic Anabolic Agents: Steroids and Nonsteroidal Selective Androgen Receptor Modulators". In Thieme D, Hemmersbach P (eds.). Doping in Sports. Springer Science & Business Media. pp. 103, 157, 162–164. ISBN 978-3-540-79088-4.
  6. ^ Potts GO, Arnold A, Beyler AL (6 December 2012). "Dissociation of the androgenic and other hormonal activities from the protein anabolic effects of steroids". In Kochakian CD (ed.). Anabolic-Androgenic Steroids. Springer Science & Business Media. pp. 380–381. doi:10.1007/978-3-642-66353-6_11. ISBN 978-3-642-66353-6.
  7. ^ Foster RH, Wilde MI (November 1998). "Dienogest". Drugs. 56 (5): 825–33, discussion 834–5. doi:10.2165/00003495-199856050-00007. PMID 9829156. S2CID 262326901.